This research report provides a comprehensive analysis of the Neurodegenerative Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Neurodegenerative Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Neurodegenerative Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Neurodegenerative Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Neurodegenerative Drugs market presents opportunities for various stakeholders, including Parkinson?s Disease, Huntington Disease. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Neurodegenerative Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Neurodegenerative Drugs market was valued at US$ 108490 million in 2023 and is projected to reach US$ 165730 million by 2030, at a CAGR of 6.2% during the forecast period.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
Key Features:
The research report on the Neurodegenerative Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Neurodegenerative Drugs market.
Market Overview: The report provides a comprehensive overview of the Neurodegenerative Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., NMDA, SSRIs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Neurodegenerative Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Neurodegenerative Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Neurodegenerative Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Neurodegenerative Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Neurodegenerative Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Neurodegenerative Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Neurodegenerative Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Neurodegenerative Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Neurodegenerative Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Market segment by Application
Parkinson?s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer?s Disease
Global Neurodegenerative Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurodegenerative Drugs, market overview.
Chapter 2: Global Neurodegenerative Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Neurodegenerative Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Neurodegenerative Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurodegenerative Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurodegenerative Drugs Overall Market Size
2.1 Global Neurodegenerative Drugs Market Size: 2023 VS 2030
2.2 Global Neurodegenerative Drugs Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Neurodegenerative Drugs Sales: 2019-2030
3 Company Landscape
3.1 Top Neurodegenerative Drugs Players in Global Market
3.2 Top Global Neurodegenerative Drugs Companies Ranked by Revenue
3.3 Global Neurodegenerative Drugs Revenue by Companies
3.4 Global Neurodegenerative Drugs Sales by Companies
3.5 Global Neurodegenerative Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Neurodegenerative Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Neurodegenerative Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neurodegenerative Drugs Players in Global Market
3.8.1 List of Global Tier 1 Neurodegenerative Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Neurodegenerative Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Neurodegenerative Drugs Market Size Markets, 2023 & 2030
4.1.2 NMDA
4.1.3 SSRIs
4.1.4 Dopamine Inhibitors
4.2 By Type - Global Neurodegenerative Drugs Revenue & Forecasts
4.2.1 By Type - Global Neurodegenerative Drugs Revenue, 2019-2024
4.2.2 By Type - Global Neurodegenerative Drugs Revenue, 2025-2030
4.2.3 By Type - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
4.3 By Type - Global Neurodegenerative Drugs Sales & Forecasts
4.3.1 By Type - Global Neurodegenerative Drugs Sales, 2019-2024
4.3.2 By Type - Global Neurodegenerative Drugs Sales, 2025-2030
4.3.3 By Type - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
4.4 By Type - Global Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neurodegenerative Drugs Market Size, 2023 & 2030
5.1.2 Parkinson?s Disease
5.1.3 Huntington Disease
5.1.4 Amyotrophic Lateral Sclerosis
5.1.5 Alzheimer?s Disease
5.2 By Application - Global Neurodegenerative Drugs Revenue & Forecasts
5.2.1 By Application - Global Neurodegenerative Drugs Revenue, 2019-2024
5.2.2 By Application - Global Neurodegenerative Drugs Revenue, 2025-2030
5.2.3 By Application - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
5.3 By Application - Global Neurodegenerative Drugs Sales & Forecasts
5.3.1 By Application - Global Neurodegenerative Drugs Sales, 2019-2024
5.3.2 By Application - Global Neurodegenerative Drugs Sales, 2025-2030
5.3.3 By Application - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
5.4 By Application - Global Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Neurodegenerative Drugs Market Size, 2023 & 2030
6.2 By Region - Global Neurodegenerative Drugs Revenue & Forecasts
6.2.1 By Region - Global Neurodegenerative Drugs Revenue, 2019-2024
6.2.2 By Region - Global Neurodegenerative Drugs Revenue, 2025-2030
6.2.3 By Region - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
6.3 By Region - Global Neurodegenerative Drugs Sales & Forecasts
6.3.1 By Region - Global Neurodegenerative Drugs Sales, 2019-2024
6.3.2 By Region - Global Neurodegenerative Drugs Sales, 2025-2030
6.3.3 By Region - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Neurodegenerative Drugs Revenue, 2019-2030
6.4.2 By Country - North America Neurodegenerative Drugs Sales, 2019-2030
6.4.3 US Neurodegenerative Drugs Market Size, 2019-2030
6.4.4 Canada Neurodegenerative Drugs Market Size, 2019-2030
6.4.5 Mexico Neurodegenerative Drugs Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Neurodegenerative Drugs Revenue, 2019-2030
6.5.2 By Country - Europe Neurodegenerative Drugs Sales, 2019-2030
6.5.3 Germany Neurodegenerative Drugs Market Size, 2019-2030
6.5.4 France Neurodegenerative Drugs Market Size, 2019-2030
6.5.5 U.K. Neurodegenerative Drugs Market Size, 2019-2030
6.5.6 Italy Neurodegenerative Drugs Market Size, 2019-2030
6.5.7 Russia Neurodegenerative Drugs Market Size, 2019-2030
6.5.8 Nordic Countries Neurodegenerative Drugs Market Size, 2019-2030
6.5.9 Benelux Neurodegenerative Drugs Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Neurodegenerative Drugs Revenue, 2019-2030
6.6.2 By Region - Asia Neurodegenerative Drugs Sales, 2019-2030
6.6.3 China Neurodegenerative Drugs Market Size, 2019-2030
6.6.4 Japan Neurodegenerative Drugs Market Size, 2019-2030
6.6.5 South Korea Neurodegenerative Drugs Market Size, 2019-2030
6.6.6 Southeast Asia Neurodegenerative Drugs Market Size, 2019-2030
6.6.7 India Neurodegenerative Drugs Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Neurodegenerative Drugs Revenue, 2019-2030
6.7.2 By Country - South America Neurodegenerative Drugs Sales, 2019-2030
6.7.3 Brazil Neurodegenerative Drugs Market Size, 2019-2030
6.7.4 Argentina Neurodegenerative Drugs Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Neurodegenerative Drugs Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Neurodegenerative Drugs Sales, 2019-2030
6.8.3 Turkey Neurodegenerative Drugs Market Size, 2019-2030
6.8.4 Israel Neurodegenerative Drugs Market Size, 2019-2030
6.8.5 Saudi Arabia Neurodegenerative Drugs Market Size, 2019-2030
6.8.6 UAE Neurodegenerative Drugs Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Neurodegenerative Drugs Major Product Offerings
7.1.4 Novartis Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Novartis Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Neurodegenerative Drugs Major Product Offerings
7.2.4 Pfizer Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.2.5 Pfizer Key News & Latest Developments
7.3 Merck Serono
7.3.1 Merck Serono Company Summary
7.3.2 Merck Serono Business Overview
7.3.3 Merck Serono Neurodegenerative Drugs Major Product Offerings
7.3.4 Merck Serono Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Merck Serono Key News & Latest Developments
7.4 Biogen Idec
7.4.1 Biogen Idec Company Summary
7.4.2 Biogen Idec Business Overview
7.4.3 Biogen Idec Neurodegenerative Drugs Major Product Offerings
7.4.4 Biogen Idec Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.4.5 Biogen Idec Key News & Latest Developments
7.5 TEVA
7.5.1 TEVA Company Summary
7.5.2 TEVA Business Overview
7.5.3 TEVA Neurodegenerative Drugs Major Product Offerings
7.5.4 TEVA Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.5.5 TEVA Key News & Latest Developments
7.6 UCB
7.6.1 UCB Company Summary
7.6.2 UCB Business Overview
7.6.3 UCB Neurodegenerative Drugs Major Product Offerings
7.6.4 UCB Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.6.5 UCB Key News & Latest Developments
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Company Summary
7.7.2 Boehringer Ingelheim Business Overview
7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Major Product Offerings
7.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.7.5 Boehringer Ingelheim Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Neurodegenerative Drugs Major Product Offerings
7.8.4 Sanofi Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Sanofi Key News & Latest Developments
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Company Summary
7.9.2 GlaxoSmithKline Business Overview
7.9.3 GlaxoSmithKline Neurodegenerative Drugs Major Product Offerings
7.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.9.5 GlaxoSmithKline Key News & Latest Developments
7.10 Livzon Pharmaceutical
7.10.1 Livzon Pharmaceutical Company Summary
7.10.2 Livzon Pharmaceutical Business Overview
7.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Livzon Pharmaceutical Key News & Latest Developments
7.11 Haisco Pharmaceutical
7.11.1 Haisco Pharmaceutical Company Summary
7.11.2 Haisco Pharmaceutical Business Overview
7.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Haisco Pharmaceutical Key News & Latest Developments
7.12 Jingxin Pharmaceutical
7.12.1 Jingxin Pharmaceutical Company Summary
7.12.2 Jingxin Pharmaceutical Business Overview
7.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.12.5 Jingxin Pharmaceutical Key News & Latest Developments
7.13 Dongcheng Biochemicals
7.13.1 Dongcheng Biochemicals Company Summary
7.13.2 Dongcheng Biochemicals Business Overview
7.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Major Product Offerings
7.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Dongcheng Biochemicals Key News & Latest Developments
7.14 Hisun Pharmaceutical
7.14.1 Hisun Pharmaceutical Company Summary
7.14.2 Hisun Pharmaceutical Business Overview
7.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.14.5 Hisun Pharmaceutical Key News & Latest Developments
7.15 Luye Pharma
7.15.1 Luye Pharma Company Summary
7.15.2 Luye Pharma Business Overview
7.15.3 Luye Pharma Neurodegenerative Drugs Major Product Offerings
7.15.4 Luye Pharma Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.15.5 Luye Pharma Key News & Latest Developments
7.16 Ark Pharmaceutical
7.16.1 Ark Pharmaceutical Company Summary
7.16.2 Ark Pharmaceutical Business Overview
7.16.3 Ark Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.16.5 Ark Pharmaceutical Key News & Latest Developments
7.17 Kanghong Pharmaceutical
7.17.1 Kanghong Pharmaceutical Company Summary
7.17.2 Kanghong Pharmaceutical Business Overview
7.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.17.5 Kanghong Pharmaceutical Key News & Latest Developments
7.18 Huahai Pharmaceutical
7.18.1 Huahai Pharmaceutical Company Summary
7.18.2 Huahai Pharmaceutical Business Overview
7.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Major Product Offerings
7.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.18.5 Huahai Pharmaceutical Key News & Latest Developments
7.19 BORA PHARMACEUTICALS
7.19.1 BORA PHARMACEUTICALS Company Summary
7.19.2 BORA PHARMACEUTICALS Business Overview
7.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Major Product Offerings
7.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales and Revenue in Global (2019-2024)
7.19.5 BORA PHARMACEUTICALS Key News & Latest Developments
8 Global Neurodegenerative Drugs Production Capacity, Analysis
8.1 Global Neurodegenerative Drugs Production Capacity, 2019-2030
8.2 Neurodegenerative Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Neurodegenerative Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Neurodegenerative Drugs Supply Chain Analysis
10.1 Neurodegenerative Drugs Industry Value Chain
10.2 Neurodegenerative Drugs Upstream Market
10.3 Neurodegenerative Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Neurodegenerative Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Neurodegenerative Drugs in Global Market
Table 2. Top Neurodegenerative Drugs Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Neurodegenerative Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Neurodegenerative Drugs Revenue Share by Companies, 2019-2024
Table 5. Global Neurodegenerative Drugs Sales by Companies, (MT), 2019-2024
Table 6. Global Neurodegenerative Drugs Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Neurodegenerative Drugs Price (2019-2024) & (US$/MT)
Table 8. Global Manufacturers Neurodegenerative Drugs Product Type
Table 9. List of Global Tier 1 Neurodegenerative Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurodegenerative Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Neurodegenerative Drugs Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Neurodegenerative Drugs Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Neurodegenerative Drugs Sales (MT), 2019-2024
Table 15. By Type - Global Neurodegenerative Drugs Sales (MT), 2025-2030
Table 16. By Application ? Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Neurodegenerative Drugs Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Neurodegenerative Drugs Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Neurodegenerative Drugs Sales (MT), 2019-2024
Table 20. By Application - Global Neurodegenerative Drugs Sales (MT), 2025-2030
Table 21. By Region ? Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Neurodegenerative Drugs Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Neurodegenerative Drugs Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Neurodegenerative Drugs Sales (MT), 2019-2024
Table 25. By Region - Global Neurodegenerative Drugs Sales (MT), 2025-2030
Table 26. By Country - North America Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Neurodegenerative Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Neurodegenerative Drugs Sales, (MT), 2019-2024
Table 29. By Country - North America Neurodegenerative Drugs Sales, (MT), 2025-2030
Table 30. By Country - Europe Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Neurodegenerative Drugs Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Neurodegenerative Drugs Sales, (MT), 2019-2024
Table 33. By Country - Europe Neurodegenerative Drugs Sales, (MT), 2025-2030
Table 34. By Region - Asia Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Neurodegenerative Drugs Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Neurodegenerative Drugs Sales, (MT), 2019-2024
Table 37. By Region - Asia Neurodegenerative Drugs Sales, (MT), 2025-2030
Table 38. By Country - South America Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Neurodegenerative Drugs Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Neurodegenerative Drugs Sales, (MT), 2019-2024
Table 41. By Country - South America Neurodegenerative Drugs Sales, (MT), 2025-2030
Table 42. By Country - Middle East & Africa Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Neurodegenerative Drugs Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Neurodegenerative Drugs Sales, (MT), 2019-2024
Table 45. By Country - Middle East & Africa Neurodegenerative Drugs Sales, (MT), 2025-2030
Table 46. Novartis Company Summary
Table 47. Novartis Neurodegenerative Drugs Product Offerings
Table 48. Novartis Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 49. Novartis Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Neurodegenerative Drugs Product Offerings
Table 52. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 53. Pfizer Key News & Latest Developments
Table 54. Merck Serono Company Summary
Table 55. Merck Serono Neurodegenerative Drugs Product Offerings
Table 56. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 57. Merck Serono Key News & Latest Developments
Table 58. Biogen Idec Company Summary
Table 59. Biogen Idec Neurodegenerative Drugs Product Offerings
Table 60. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 61. Biogen Idec Key News & Latest Developments
Table 62. TEVA Company Summary
Table 63. TEVA Neurodegenerative Drugs Product Offerings
Table 64. TEVA Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 65. TEVA Key News & Latest Developments
Table 66. UCB Company Summary
Table 67. UCB Neurodegenerative Drugs Product Offerings
Table 68. UCB Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 69. UCB Key News & Latest Developments
Table 70. Boehringer Ingelheim Company Summary
Table 71. Boehringer Ingelheim Neurodegenerative Drugs Product Offerings
Table 72. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 73. Boehringer Ingelheim Key News & Latest Developments
Table 74. Sanofi Company Summary
Table 75. Sanofi Neurodegenerative Drugs Product Offerings
Table 76. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 77. Sanofi Key News & Latest Developments
Table 78. GlaxoSmithKline Company Summary
Table 79. GlaxoSmithKline Neurodegenerative Drugs Product Offerings
Table 80. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 81. GlaxoSmithKline Key News & Latest Developments
Table 82. Livzon Pharmaceutical Company Summary
Table 83. Livzon Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 84. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 85. Livzon Pharmaceutical Key News & Latest Developments
Table 86. Haisco Pharmaceutical Company Summary
Table 87. Haisco Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 88. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 89. Haisco Pharmaceutical Key News & Latest Developments
Table 90. Jingxin Pharmaceutical Company Summary
Table 91. Jingxin Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 92. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 93. Jingxin Pharmaceutical Key News & Latest Developments
Table 94. Dongcheng Biochemicals Company Summary
Table 95. Dongcheng Biochemicals Neurodegenerative Drugs Product Offerings
Table 96. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 97. Dongcheng Biochemicals Key News & Latest Developments
Table 98. Hisun Pharmaceutical Company Summary
Table 99. Hisun Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 100. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 101. Hisun Pharmaceutical Key News & Latest Developments
Table 102. Luye Pharma Company Summary
Table 103. Luye Pharma Neurodegenerative Drugs Product Offerings
Table 104. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 105. Luye Pharma Key News & Latest Developments
Table 106. Ark Pharmaceutical Company Summary
Table 107. Ark Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 108. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 109. Ark Pharmaceutical Key News & Latest Developments
Table 110. Kanghong Pharmaceutical Company Summary
Table 111. Kanghong Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 112. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 113. Kanghong Pharmaceutical Key News & Latest Developments
Table 114. Huahai Pharmaceutical Company Summary
Table 115. Huahai Pharmaceutical Neurodegenerative Drugs Product Offerings
Table 116. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 117. Huahai Pharmaceutical Key News & Latest Developments
Table 118. BORA PHARMACEUTICALS Company Summary
Table 119. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Offerings
Table 120. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (US$, Mn) and Average Price (US$/MT) (2019-2024)
Table 121. BORA PHARMACEUTICALS Key News & Latest Developments
Table 122. Neurodegenerative Drugs Production Capacity (MT) of Key Manufacturers in Global Market, 2022-2024 (MT)
Table 123. Global Neurodegenerative Drugs Capacity Market Share of Key Manufacturers, 2022-2024
Table 124. Global Neurodegenerative Drugs Production by Region, 2019-2024 (MT)
Table 125. Global Neurodegenerative Drugs Production by Region, 2025-2030 (MT)
Table 126. Neurodegenerative Drugs Market Opportunities & Trends in Global Market
Table 127. Neurodegenerative Drugs Market Drivers in Global Market
Table 128. Neurodegenerative Drugs Market Restraints in Global Market
Table 129. Neurodegenerative Drugs Raw Materials
Table 130. Neurodegenerative Drugs Raw Materials Suppliers in Global Market
Table 131. Typical Neurodegenerative Drugs Downstream
Table 132. Neurodegenerative Drugs Downstream Clients in Global Market
Table 133. Neurodegenerative Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Neurodegenerative Drugs Segment by Type in 2023
Figure 2. Neurodegenerative Drugs Segment by Application in 2023
Figure 3. Global Neurodegenerative Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Neurodegenerative Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Neurodegenerative Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. Neurodegenerative Drugs Sales in Global Market: 2019-2030 (MT)
Figure 8. The Top 3 and 5 Players Market Share by Neurodegenerative Drugs Revenue in 2023
Figure 9. By Type - Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 11. By Type - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 12. By Type - Global Neurodegenerative Drugs Price (US$/MT), 2019-2030
Figure 13. By Application - Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 15. By Application - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 16. By Application - Global Neurodegenerative Drugs Price (US$/MT), 2019-2030
Figure 17. By Region - Global Neurodegenerative Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Neurodegenerative Drugs Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 20. By Region - Global Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 21. By Country - North America Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 22. By Country - North America Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 23. US Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 28. Germany Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. France Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 37. China Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. India Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 43. By Country - South America Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 44. Brazil Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Neurodegenerative Drugs Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Neurodegenerative Drugs Sales Market Share, 2019-2030
Figure 48. Turkey Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Neurodegenerative Drugs Revenue, (US$, Mn), 2019-2030
Figure 52. Global Neurodegenerative Drugs Production Capacity (MT), 2019-2030
Figure 53. The Percentage of Production Neurodegenerative Drugs by Region, 2023 VS 2030
Figure 54. Neurodegenerative Drugs Industry Value Chain
Figure 55. Marketing Channels
